インスリングラルギン (Japanese Wikipedia)

Analysis of information sources in references of the Wikipedia article "インスリングラルギン" in Japanese language version.

refsWebsite

Global rank Japanese rank

14nih.gov

4^th place

24^th place

8doi.org

2^nd place

6^th place

4europa.eu

68^th place

425^th place

3drugs.com

399^th place

1,603^rd place

3pmda.go.jp

6,690^th place

394^th place

2web.archive.org

1^st place

1medicines.org.uk

3,823^rd place

low place

1handle.net

102^nd place

78^th place

1warwick.ac.uk

4,378^th place

low place

1springer.com

274^th place

596^th place

1harvard.edu

18^th place

107^th place

1sanofi.us

low place

1fda.gov

447^th place

1,043^rd place

1dm-net.co.jp

low place

dm-net.co.jp

“次世代の基礎インスリン「ランタスXR注ソロスター」承認取得低血糖発現と体重増加が低下｜ニュース｜糖尿病ネットワーク”. ニュース｜糖尿病ネットワーク. 2022年1月19日閲覧。

doi.org

Waugh, N; Cummins, E; Royle, P; Clar, C; Marien, M; Richter, B; Philip, S (July 2010). “Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation”. Health Technology Assessment 14 (36): 1–248. doi:10.3310/hta14360. PMID 20646668.
“Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis”. CMAJ 180 (4): 385–97. (February 2009). doi:10.1503/cmaj.081041. PMC 2638025. PMID 19221352.
“Cost-Effectiveness of Insulin Degludec Versus Insulin Glargine U300 in the Netherlands: Evidence From a Randomised Controlled Trial”. Advances in Therapy 37 (5): 2413-2426. (April 2020). doi:10.1007/s12325-020-01332-y. PMC 7467476. PMID 32306247.
American Diabetes Association (2003). “Position statement: Insulin administration”. Diabetes Care 26 (Suppl. 1): 121–124. doi:10.2337/diacare.26.2007.S121. PMID 12502637.
Kaplan, W. (2004). “Effects of Mixing Glargine and Short-Acting Insulin Analogs on Glucose Control”. Diabetes Care 27 (11): 2739–2740. doi:10.2337/diacare.27.11.2739. PMID 15505016.
Rendell, M; Akturk, HK; Tella, SH (March 2013). “Glargine safety, diabetes and cancer.”. Expert Opinion on Drug Safety 12 (2): 247–63. doi:10.1517/14740338.2013.770469. PMID 23394441.
Tang, X; Yang, L; He, Z; Liu, J (2012). “Insulin glargine and cancer risk in patients with diabetes: a meta-analysis.”. PLOS ONE 7 (12): e51814. Bibcode: 2012PLoSO...751814T. doi:10.1371/journal.pone.0051814. PMC 3526637. PMID 23284776.
Bolli, G. (1999). “Insulin analogues and their potential in the management of diabetes mellitus.”. Diabetologia 42 (10): 1151–1167. doi:10.1007/s001250051286. PMID 10525654.

drugs.com

“Insulin glargine Use During Pregnancy”. Drugs.com (6 April 2020). 4 September 2020閲覧。
“Insulin Glargine Monograph for Professionals”. Drugs.com. AHFS. 23 December 2018閲覧。
“Insulin Glargine Monograph for Professionals”. Drugs.com. AHFS. 23 December 2018閲覧。

europa.eu

ema.europa.eu

“Lantus EPAR”. European Medicines Agency (EMA). 28 July 2021閲覧。
“Toujeo EPAR”. European Medicines Agency (EMA). 28 July 2021閲覧。
“Lantus EPAR”. European Medicines Agency (EMA). 7 May 2020閲覧。

emea.europa.eu

EPAR Lantus Archived 22 November 2006 at the Wayback Machine., German summary of admission report of EMEA (PDF)

fda.gov

accessdata.fda.gov

“Toujeo: FDA-Approved Drugs”. U.S. Food and Drug Administration (FDA). 7 May 2020閲覧。

handle.net

hdl.handle.net

World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. (2021). hdl:10665/345533. WHO/MHP/HPS/EML/2021.02

harvard.edu

ui.adsabs.harvard.edu

Tang, X; Yang, L; He, Z; Liu, J (2012). “Insulin glargine and cancer risk in patients with diabetes: a meta-analysis.”. PLOS ONE 7 (12): e51814. Bibcode: 2012PLoSO...751814T. doi:10.1371/journal.pone.0051814. PMC 3526637. PMID 23284776.

medicines.org.uk

“Lantus 100 units/ml solution for injection in a cartridge - Summary of Product Characteristics (SmPC)”. (emc). 7 May 2020閲覧。

nih.gov

pubmed.ncbi.nlm.nih.gov

Waugh, N; Cummins, E; Royle, P; Clar, C; Marien, M; Richter, B; Philip, S (July 2010). “Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation”. Health Technology Assessment 14 (36): 1–248. doi:10.3310/hta14360. PMID 20646668.
“Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis”. CMAJ 180 (4): 385–97. (February 2009). doi:10.1503/cmaj.081041. PMC 2638025. PMID 19221352.
“Cost-Effectiveness of Insulin Degludec Versus Insulin Glargine U300 in the Netherlands: Evidence From a Randomised Controlled Trial”. Advances in Therapy 37 (5): 2413-2426. (April 2020). doi:10.1007/s12325-020-01332-y. PMC 7467476. PMID 32306247.
American Diabetes Association (2003). “Position statement: Insulin administration”. Diabetes Care 26 (Suppl. 1): 121–124. doi:10.2337/diacare.26.2007.S121. PMID 12502637.
Kaplan, W. (2004). “Effects of Mixing Glargine and Short-Acting Insulin Analogs on Glucose Control”. Diabetes Care 27 (11): 2739–2740. doi:10.2337/diacare.27.11.2739. PMID 15505016.
Rendell, M; Akturk, HK; Tella, SH (March 2013). “Glargine safety, diabetes and cancer.”. Expert Opinion on Drug Safety 12 (2): 247–63. doi:10.1517/14740338.2013.770469. PMID 23394441.
Tang, X; Yang, L; He, Z; Liu, J (2012). “Insulin glargine and cancer risk in patients with diabetes: a meta-analysis.”. PLOS ONE 7 (12): e51814. Bibcode: 2012PLoSO...751814T. doi:10.1371/journal.pone.0051814. PMC 3526637. PMID 23284776.
Bolli, G. (1999). “Insulin analogues and their potential in the management of diabetes mellitus.”. Diabetologia 42 (10): 1151–1167. doi:10.1007/s001250051286. PMID 10525654.

pmc.ncbi.nlm.nih.gov

ncbi.nlm.nih.gov

dailymed.nlm.nih.gov

“Lantus- insulin glargine injection, solution Lantus SoloStar- insulin glargine injection, solution”. DailyMed. 29 July 2021閲覧。

pmda.go.jp

info.pmda.go.jp

“ランタス注100単位／mL 添付文書”. www.info.pmda.go.jp. 2022年1月19日閲覧。
“ランタスXR注ソロスター添付文書”. www.info.pmda.go.jp. 2022年1月19日閲覧。

pmda.go.jp

“ランタスXR注ソロスター CTD 第二部”. PMDA. 2022年1月19日閲覧。

sanofi.us

news.sanofi.us

"Sanofi Receives FDA Approval of Once-Daily Basal Insulin Toujeo" (Press release). Sanofi. 25 February 2015. 2015年2月27日時点のオリジナルよりアーカイブ。

springer.com

link.springer.com

“Cost-Effectiveness of Insulin Degludec Versus Insulin Glargine U300 in the Netherlands: Evidence From a Randomised Controlled Trial”. Advances in Therapy 37 (5): 2413-2426. (April 2020). doi:10.1007/s12325-020-01332-y. PMC 7467476. PMID 32306247.

warwick.ac.uk

wrap.warwick.ac.uk

Waugh, N; Cummins, E; Royle, P; Clar, C; Marien, M; Richter, B; Philip, S (July 2010). “Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation”. Health Technology Assessment 14 (36): 1–248. doi:10.3310/hta14360. PMID 20646668.

web.archive.org

EPAR Lantus Archived 22 November 2006 at the Wayback Machine., German summary of admission report of EMEA (PDF)
"Sanofi Receives FDA Approval of Once-Daily Basal Insulin Toujeo" (Press release). Sanofi. 25 February 2015. 2015年2月27日時点のオリジナルよりアーカイブ。

インスリン グラルギン (Japanese Wikipedia)

dm-net.co.jp

doi.org

drugs.com

europa.eu

ema.europa.eu

emea.europa.eu

fda.gov

accessdata.fda.gov

handle.net

hdl.handle.net

harvard.edu

ui.adsabs.harvard.edu

medicines.org.uk

nih.gov

pubmed.ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov

ncbi.nlm.nih.gov

dailymed.nlm.nih.gov

pmda.go.jp

info.pmda.go.jp

pmda.go.jp

sanofi.us

news.sanofi.us

springer.com

link.springer.com

warwick.ac.uk

wrap.warwick.ac.uk

web.archive.org

インスリングラルギン (Japanese Wikipedia)